Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

Core Insights - The business combination of Recursion and Exscientia has been completed, creating a vertically-integrated and technology-enabled drug discovery platform [1][2] - The combined entity will focus on first and best-in-class drug discovery and development, leveraging AI to reduce time and costs [1][2] Pipeline - The combined pipeline includes more than 10 clinical and preclinical programs, along with approximately 10 advanced discovery programs [3][4] - Key upcoming milestones include initial Phase 1 data for REC-617 expected on December 9, 2024, and various updates for other candidates throughout 2025 and 2026 [4][5] Partnerships - The company has over 10 partnered programs in oncology and immunology, with approximately $450 million received in upfront and milestone payments to date [6][7] - Potential future milestone payments from partnerships could exceed $20 billion [6][7] Platform - The integration of Exscientia's chemical design methods and Recursion's extensive proprietary data (over 60 petabytes) will enhance the Recursion Operating System (OS) for drug discovery [8][9] - The platform aims to create virtual cells for executing clinical trials at scale, driving iterative learning from research to development [9] Company Structure and Leadership - The combined company will have around 800 employees, with headquarters in Salt Lake City and additional offices in various locations [10] - Leadership changes include appointments of former Exscientia executives to key positions within Recursion [10]